INTRODUCTION. Oxygen treatment of hypoxaemia is considered an essential part of the treatment of patients who are acutely admitted with medical conditions affecting cardiovascular and/or pulmonary function. Despite the important role of oxygen
administration for these patients, clinical evidence on how to control supplemental oxygen to avoid hypoxaemia and
hyperoxia is limited. We aim to investigate whether an automatic closed-loop oxygen administration system (O2matic) may maintain normoxaemia better than usual care.
METHODS. This study will be an investigator-initiated, prospective, randomised clinical trial. The patients are randomised
during admission after informed consent is obtained, at a 1:1 ratio with conventional oxygen treatment or O2matic oxygen
treatment for 24 hours. The primary outcome is time within the desired peripheral capillary oxygen saturation interval: 92- 96%.
CONCLUSION. This study will examine the clinical applicability of a novel automated feedback device termed O2matic and
assess whether the device is superior to standard care in keeping the patients in the optimal saturation interval. We hypothesise that the O2matic will increase time within the desired saturation interval.
FUNDING. Johannes Grand’s salary during this project is supported by a research grant from the Danish Cardiovascular Academy funded by Novo Nordisk Foundation grant number NNF20SA0067242 and by The Danish Heart Foundation.
TRIAL REGISTRATION. ClinicalTrials.gov (ClinicalTrials.gov Identifier: NCT05452863). Registered on 11 July 2022.